8-K: Cassava Sciences Appoints Biopharma Veteran Dawn Bir to Board

Cassava Sciences, Inc. has expanded its Board of Directors to eight members with the appointment of seasoned biopharmaceutical executive Dawn C. Bir.

Summary

• Cassava Sciences, Inc. announced the appointment of Dawn C. Bir to its Board of Directors, effective October 21, 2025.
• The Board of Directors has been expanded to eight members with this appointment.
• Ms. Bir was appointed as a Class I director, with her term expiring at the company's 2028 annual meeting of stockholders.
• She has not yet been appointed to any Board committees.
• Ms. Bir is eligible for compensation under the company's Non-employee Director Compensation Program and has executed a standard indemnification agreement.
• The appointment aims to augment the Board with additional strategic capabilities as the company prepares to initiate its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced biopharmaceutical executive to the Board is a positive development, strengthening the company's strategic capabilities as it approaches a significant clinical milestone. While not directly impacting financials, it signals proactive management and strategic planning for future growth and commercialization.

Positives

• Dawn Bir brings over two decades of experience as a seasoned biopharmaceutical executive and board member, with a strong track record in successful development and value creation for pre-commercial and commercial biotechnology companies.
• Her expertise in forging influential relationships with market stakeholders and creating a clear line of sight from clinic to commercialization is expected to be invaluable as Cassava advances its TSC-related epilepsy program.
• The appointment strengthens the Board's strategic capabilities, which is crucial as the company approaches a significant clinical milestone with simufilam.
• Ms. Bir's prior roles at companies like Reata Pharmaceuticals (acquired by Biogen) and Pharmacyclics (acquired by AbbVie) demonstrate her experience in contributing to significant company growth and industry-defining exits.

Risks

• The ability to advance preclinical studies related to TSC-related epilepsy and other potential indications is uncertain.
• The company's ability to successfully carry out its obligations under the Yale License Agreement is a risk.
• There is a risk regarding the ability to initiate an initial proof-of-concept study of simufilam in TSC-related epilepsy.
• Drug discovery and development inherently involve a high degree of risk, are long, complex, and costly.
• Clinical results from earlier-stage trials or preclinical studies may not be indicative of future results from later-stage or larger-scale clinical trials and do not ensure regulatory approval.
• Investors are cautioned that they should not rely upon forward-looking statements as predictions of future events and that investing in publicly traded securities carries the risk of total loss.

Future Outlook

The company anticipates initiating its first clinical study for simufilam in TSC-related epilepsy in the first half of 2026. Management believes the new director's expertise will be crucial in guiding business and clinical strategies to bring this potential treatment to patients and families.

Management Comments

• Claude Nicaise, MD, Chairman of the Board, stated, "We are delighted to welcome Dawn to the Board at this pivotal time for Cassava. Her commitment to building shareholder value will be a great asset to the Board and the Company, and we look forward to her contributions."
• Rick Barry, President and Chief Executive Officer, commented, "As Cassava prepares to initiate our first clinical study for simufilam in TSC-related epilepsy in the first half of 2026, we believe it is important to augment our Board with additional strategic capabilities. Dawns track record of forging influential relationships with market stakeholders and creating a clear line of sight from the clinic to commercialization will be invaluable to Cassava as we advance the TSC-related epilepsy program."
• Dawn Bir, Independent Director, noted, "The profound need to deliver a transformative new therapy for TSC-related epilepsy is a powerful call to act. With Cassavas first clinical study for simufilam in TSC-related epilepsy on the horizon, I am thrilled to work with Rick and Cassavas dedicated management team and Board to guide our business and clinical strategies and help bring this much-needed potential treatment to patients and families."

Industry Context

The appointment of a seasoned biopharmaceutical executive with a strong commercialization background aligns with a common industry trend where companies, particularly those in clinical development, seek to strengthen their boards with expertise in market access and strategic relationships as they approach potential commercialization milestones. This move suggests Cassava is strategically preparing for the later stages of drug development and potential market entry for its CNS disorder treatments.

Comparison to Industry Standards

• Ms. Bir's experience includes key executive leadership roles at Reata Pharmaceuticals, Inc., which was acquired by Biogen Inc., demonstrating her ability to contribute to successful exits and value creation in the biopharmaceutical sector.
• Her tenure as Vice President of Sales at Pharmacyclics, LLC, contributed to commercial success prior to its acquisition by AbbVie, Inc., showcasing her expertise in commercial strategy within the industry.
• She currently serves as a Non-Executive Board Director for Geron Corporation (GERN) and Soleno Therapeutics, Inc. (SLNO), indicating her continued involvement and recognition within the biotech board community.
• Her background with industry leaders like McKesson Corporation, Genentech (now part of Roche Holdings AG), and Bristol-Myers Squibb Company provides a broad perspective on pharmaceutical operations and market dynamics, comparable to the leadership profiles sought by other growing biotech firms.

Management Changes

Corporate Governance

Related Party Transactions

• There are no arrangements or understandings between Ms. Bir and any other person pursuant to which she was appointed to the Board.
• Ms. Bir does not have direct or indirect material interests in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: The appointment of an experienced director with a track record of value creation is intended to benefit shareholders by strengthening strategic oversight and commercialization efforts.
• Patients and Families: The new director's expertise is expected to help guide clinical and business strategies to bring a much-needed potential treatment for TSC-related epilepsy to patients and families.

Next Steps

• Initiate the first clinical study for simufilam in TSC-related epilepsy in the first half of 2026.

Key Dates

Recommendation

The appointment of a new director, while a positive step for corporate governance and strategic planning, is typically not a standalone event that warrants a 'buy' or 'sell' recommendation. It strengthens the board's capabilities, particularly in commercialization, which is beneficial for the long-term outlook, but does not provide immediate catalysts for significant price movement. Investors should 'hold' and monitor the progress of the clinical studies and the impact of the new director's contributions over time.

Keywords

Cassava Sciences, SAVA, Board of Directors, Director Appointment, Biotechnology, CNS disorders, Tuberous Sclerosis Complex, TSC-related epilepsy, Simufilam, Clinical study, Corporate Governance